StockNews.AI
MRNA
StockNews.AI
134 days

Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

1. Moderna will present research on multiple infectious diseases at ESCMID 2025. 2. Twelve scientific presentations will showcase advancements in COVID-19, RSV, and more.

2m saved
Insight
Article

FAQ

Why Bullish?

Strong visibility and research advancements may boost investor confidence, recalling the positive impact of previous announcements on MRNA's price.

How important is it?

Research presentations can enhance MRNA's reputation and investor appeal, potentially impacting stock performance positively.

Why Short Term?

The immediate exposure at the conference could lead to short-term price fluctuations based on market reactions.

Related Companies

PFENVAXJNJ
CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, Austria, from April 11-15, 2025. Moderna will present twelve scientific presentations at the ESCMID 2025 Global Congress, including three oral presentations, one e-poster presentation, and eight poster presentations, highlighting the breadth of its research in respiratory and emerging infectious diseases.

Related News